Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDX NASDAQ:FOLD NASDAQ:LGND NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$33.32-3.1%$31.52$18.00▼$35.79$2.62B0.98932,147 shs886,212 shsFOLDAmicus Therapeutics$14.49$14.42$5.51▼$14.50$4.55B0.482.62 million shs5.29 million shsLGNDLigand Pharmaceuticals$210.33-9.6%$211.74$98.89▼$247.38$4.21B1.2227,675 shs644,039 shsZBIOZenas BioPharma$19.27-7.5%$22.12$8.53▼$44.60$1.11B-0.61886,499 shs448,451 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+1.57%+7.00%+9.63%+52.30%+86.90%FOLDAmicus Therapeutics0.00%0.00%+0.28%+1.47%+134.09%LGNDLigand Pharmaceuticals+0.11%+3.42%+14.21%+21.32%+125.08%ZBIOZenas BioPharma+0.34%+18.69%-6.42%-0.86%+130.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$33.32-3.1%$31.52$18.00▼$35.79$2.62B0.98932,147 shs886,212 shsFOLDAmicus Therapeutics$14.49$14.42$5.51▼$14.50$4.55B0.482.62 million shs5.29 million shsLGNDLigand Pharmaceuticals$210.33-9.6%$211.74$98.89▼$247.38$4.21B1.2227,675 shs644,039 shsZBIOZenas BioPharma$19.27-7.5%$22.12$8.53▼$44.60$1.11B-0.61886,499 shs448,451 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+1.57%+7.00%+9.63%+52.30%+86.90%FOLDAmicus Therapeutics0.00%0.00%+0.28%+1.47%+134.09%LGNDLigand Pharmaceuticals+0.11%+3.42%+14.21%+21.32%+125.08%ZBIOZenas BioPharma+0.34%+18.69%-6.42%-0.86%+130.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.83Moderate Buy$46.3639.15% UpsideFOLDAmicus Therapeutics 2.08Hold$14.560.50% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$256.2921.85% UpsideZBIOZenas BioPharma 2.44Hold$44.14129.08% UpsideCurrent Analyst Ratings BreakdownLatest ZBIO, LGND, FOLD, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/30/2026LGNDLigand Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$243.00 ➝ $289.004/28/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$235.00 ➝ $252.004/20/2026CLDXCelldex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Overweight$24.00 ➝ $45.004/15/2026LGNDLigand Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$276.00 ➝ $282.004/14/2026LGNDLigand Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$239.00 ➝ $243.003/27/2026FOLDAmicus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ZBIOZenas BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026LGNDLigand Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $276.003/23/2026CLDXCelldex Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$44.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$1.54M1,698.24N/AN/A$7.93 per share4.20FOLDAmicus Therapeutics$634.21M7.17$0.06 per share234.67$0.87 per share16.66LGNDLigand Pharmaceuticals$268.09M15.72$7.11 per share29.58$51.68 per share4.07ZBIOZenas BioPharma$10M110.55N/AN/A$4.51 per share4.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$258.76M-$3.89N/AN/AN/AN/A-41.67%-38.86%5/7/2026 (Estimated)FOLDAmicus Therapeutics-$27.11M-$0.08N/A18.82N/A-4.27%4.15%1.09%5/7/2026 (Estimated)LGNDLigand Pharmaceuticals$124.45M$5.8336.0828.501.6846.42%13.86%10.18%5/7/2026 (Estimated)ZBIOZenas BioPharma-$377.74M-$7.81N/AN/AN/AN/A-85.64%-61.86%5/14/2026 (Estimated)Latest ZBIO, LGND, FOLD, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ZBIOZenas BioPharma-$1.37N/AN/AN/A$25.00 millionN/A5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1322-$1.18-$0.0478-$1.18$0.80 million$0.02 million5/7/2026Q1 2026FOLDAmicus Therapeutics$0.0467N/AN/AN/A$163.71 millionN/A5/7/2026Q1 2026LGNDLigand Pharmaceuticals$1.84$1.63-$0.21-$0.67$59.10 million$51.72 million4/13/2026Q4 2025ZBIOZenas BioPharmaN/A-$1.10N/A-$0.98$40.00 millionN/A3/16/2026Q4 2025ZBIOZenas BioPharma-$1.22-$4.54-$3.32-$4.54$28.75 millionN/A2/26/2026Q4 2025LGNDLigand Pharmaceuticals$1.46$2.02+$0.56$2.12$55.59 million$59.67 million2/25/2026Q4 2025CLDXCelldex Therapeutics-$1.00-$1.22-$0.22-$1.22$1.53 million$0.12 million2/20/2026Q4 2025FOLDAmicus Therapeutics$0.13$0.10-$0.03$0.00$185.00 million$185.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A10.4810.49FOLDAmicus Therapeutics1.432.841.88LGNDLigand Pharmaceuticals0.4422.2321.98ZBIOZenas BioPharma0.325.615.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AFOLDAmicus TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics4.40%FOLDAmicus Therapeutics2.20%LGNDLigand Pharmaceuticals7.00%ZBIOZenas BioPharma22.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15078.49 million75.04 millionOptionableFOLDAmicus Therapeutics480314.00 million307.09 millionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableZBIOZenas BioPharmaN/A57.37 million44.75 millionN/AZBIO, LGND, FOLD, and CLDX HeadlinesRecent News About These CompaniesZenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on ThursdayMay 7 at 3:06 AM | americanbankingnews.comZenas BioPharma (ZBIO) to Release Quarterly Earnings on ThursdayMay 7 at 3:03 AM | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.7% - Still a Buy?May 4 at 4:32 PM | marketbeat.comLeon Moulder, Jr. Purchases 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) StockMay 1, 2026 | americanbankingnews.comLeon Moulder, Jr. Buys 35,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) StockMay 1, 2026 | americanbankingnews.comZenas BioPharma rises as CEO continues insider purchasesApril 30, 2026 | msn.comZenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026April 30, 2026 | seekingalpha.comZenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying ActivityApril 30, 2026 | marketbeat.comLeon Moulder, Jr. Buys 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) StockApril 30, 2026 | insidertrades.comLeon Moulder Jr Purchases 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) StockApril 29, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) CEO Acquires $616,700.00 in StockApril 29, 2026 | marketbeat.comHere’s Why Zenas BioPharma (ZBIO) Traded Lower in Q1April 21, 2026 | insidermonkey.comZenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Hold" by AnalystsApril 20, 2026 | marketbeat.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 17, 2026 | markets.businessinsider.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 17, 2026 | globenewswire.comZenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 21.4% in MarchApril 17, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Issues Quarterly Earnings ResultsApril 14, 2026 | marketbeat.comMorgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)April 10, 2026 | theglobeandmail.comZenas BioPharma (NASDAQ:ZBIO) Shares Down 7% - Should You Sell?April 8, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Director Purchases $70,197.84 in StockApril 3, 2026 | insidertrades.comZenas BioPharma's Key Milestones And Market Context: Holding Through The BLAApril 3, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 2026Apple’s Hinge Cringe: Foldable Flop or Strategic Stop? By Jeffrey Neal Johnson | April 9, 2026Apple's Foldable iPhone Foray: A Real Needle Mover or Hype Train?By Leo Miller | April 15, 2026ZBIO, LGND, FOLD, and CLDX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$33.32 -1.07 (-3.11%) Closing price 04:00 PM EasternExtended Trading$33.33 +0.01 (+0.03%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Amicus Therapeutics NASDAQ:FOLD$14.49 0.00 (0.00%) As of 04/27/2026Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$210.33 -22.22 (-9.55%) Closing price 04:00 PM EasternExtended Trading$210.22 -0.12 (-0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Zenas BioPharma NASDAQ:ZBIO$19.27 -1.56 (-7.49%) Closing price 04:00 PM EasternExtended Trading$19.27 0.00 (0.00%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
